CStone Pharmaceuticals Reports First Half 2019 Financial Results
SHANGHAI, Aug. 15, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone"; HKEX: 2616), a leading biopharmaceutical company focused on developing and commercializing innovative immuno-oncology therapies and molecularly-targeted drugs for the treatment of cancer, today released its recent business ...
CStone announces first patient dosed in China with BLU-667 for the global Phase I registrational study
SUZHOU, China, Aug. 13, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616) today announces the dosing of the first patient inChina for the Phase I registrational study of BLU-667, which was discovered by the company's partner Blueprint Medicines. This clinical trial is a part of t...
CStone to Build Global R&D Headquarters and Industrialization Base in the Suzhou Industrial Park
SUZHOU, China, Aug. 7, 2019 /PRNewswire/ -- The signing ceremony for CStone Pharmaceuticals' ("CStone") (HKEX: 2616) Global R&D Headquarters and Industrialization Base ("the Project") took place in Suzhouon August 6. The event marks the building of yet another state-of-the-art research and devel...
CStone receives approval in China to initiate ivosidenib Phase I bridging registrational study for the treatment of IDH1 mutant relapsed or refractory AML
SUZHOU, China, July 22, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone"; HKEX: 2616) announced today that it has received approval from China National Medical Products Administration (NMPA) to initiate a Phase I bridging registrational study of ivosidenib (TIBSOVO) for the treatment of rela...
CStone announces first patient dosed in China with avapritinib in global Phase III clinical trial in advanced GIST
SUZHOU, China, July 9, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616) today announced that the first patient has been dosed inChina with avapritinib in the ongoing global Phase III VOYAGER clinical trial. This study is designed to evaluate the safety and efficacy of avapritini...
CStone and Bayer announce global collaboration to evaluate PD-L1 monoclonal antibody CS1001 in combination with regorafenib
SUZHOU, China, June 9, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone"; HKEX: 2616) today announced that the company has entered into a global clinical collaboration withChina focus with Bayer HealthCare LLC to evaluate the safety, tolerability, pharmacokinetics (PK) and antitumor activity ...
CStone received approval to initiate clinical development in China of CS1001 and BLU-554 (CS3008) in combination therapy for HCC
SUZHOU, China, June 5, 2019 /PRNewswire/ -- CStone Pharmaceuticals (CStone; HKEX: 2616) announced that it has received approval to initiate clinical development inChina of CS1001 in combination with BLU-554 (CS3008) in patients with locally advanced or metastatic hepatocellular carcinoma (HCC). T...
CStone submits new drug application for TIBSOVO(R) in Taiwan for the treatment of relapsed/refractory AML
HONG KONG, June 2, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616) announced that a new drug application (NDA) for TIBSOVO® (ivosidenib) has been submitted by a third-party to the Taiwan Food and Drug Administration (TFDA) as the first to-be-approved treatment of adult patients...
Cstone partner Agios Announces the Phase 3 ClarIDHy Trial of TIBSOVO (ivosidenib) Achieved its Primary Endpoint
SUZHOU, China, May 23, 2019 /PRNewswire/ -- The partner of CStone Pharmaceuticals ("Cstone"; HKEX:2616), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) ("Agios") announced that the global Phase 3 ClarIDHy trial of TIBSOVO (ivosidenib) in previously treated cholangiocarcinoma patients with an isocitr...
CStone and Numab announce exclusive regional licensing agreement for ND021, a multi-functional drug candidate and potential next-generation immunotherapy
SUZHOU, China and ZURICH, May 2, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone"; HKEX: 2616) and Numab Therapeutics AG ("Numab") today announce that they have entered into an exclusive regional licensing agreement for the development and commercialization of ND021, a potential best-in-clas...
First patient dosed in Phase III GEMSTONE-303 study for CS1001 in combination with chemotherapy in first-line gastric adenocarcinoma and gastro-esophageal junction adenocarcinoma
SHANGHAI, April 16, 2019 /PRNewswire/ -- CStone Pharmaceuticals (the "Company" or "CStone"; HKEX: 2616) announces that the first patient has been successfully enrolled and dosed in a Phase III clinical trial assessing CS1001,China's first fully human, full-length anti-PD-L1 antibody, in combinati...
CStone received IND approval in China for avapritinib Phase I/II bridging registrational study in patients with advanced gastrointestinal stromal tumors
SHANGHAI, April 15, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone"; HKEX: 2616) announced today that the National Medical Products Administration (NMPA) recently approved the initiation of a Phase I/II clinical trial inChina evaluating avapritinib, a drug candidate discovered by the compan...
CStone Pharmaceuticals presented poster of pre-clinical result for CS1003 at AACR
SHANGHAI, April 4, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone"; HKEX:2616) delivered a poster of pre-clinical data of CS1003 at the 2019 American Association for Cancer Research (AACR) Annual Meeting. CS1003 is a humanized IgG4 PD-1 monoclonal antibody designed to block the interaction...
CStone appoints three distinguished oncology leaders Drs. Paul A. Bunn, Jr., Elizabeth M. Jaffee and Richard S. Finn to its Scientific Advisory Board
SHANGHAI, March 25, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone"; HKEX: 2616) is pleased to announce the appointment of three internationally renowned oncologistsPaul A. Bunn, Jr., MD, Elizabeth M. Jaffee, MD, and Richard S. Finn, MD, as the company's Scientific Advisory Board (SAB) memb...
CStone receives approval in China to initiate Phase 1 clinical trial for RET inhibitor BLU-667 (CS3009)
SUZHOU, China, March 21, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone"; HKEX: 2616) today announced thatChina's National Medical Products Administration (NMPA) has approved the clinical trial application to begin a Phase 1 trial inChina for BLU-667 (CS3009), a highly selective and potent ...
CStone received IND approval in China for HDAC6 inhibitor CS3003
SUZHOU, China, March 13, 2019 /PRNewswire/ -- CStone Pharmaceuticals (Suzhou) Co., Ltd. ("CStone", stock code: 2616.HK) announced that the National Medical Products Administration (NMPA) recently approved company's histone deacetylase 6 (HDAC6) selective inhibitor CS3003 for Phase I clinical tria...
CStone Pharmaceuticals listed on the Hong Kong Stock Exchange today
HONG KONG, Feb. 26, 2019 /PRNewswire/ -- CStone Pharmaceuticals (Stock code: 2616) today announced the listing of 186,396,000 shares on the Main Board of the Hong Kong Stock Exchange. Based on the offer price ofHK$12.00 per share, the net proceeds to be received by the Company are aboutHK$2,085...